UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Holdings in Chemed Co. (NYSE:CHE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Chemed Co. (NYSE:CHE - Free Report) by 5.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 48,197 shares of the company's stock after purchasing an additional 2,277 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.32% of Chemed worth $25,535,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in CHE. Atala Financial Inc bought a new stake in shares of Chemed in the 4th quarter valued at $29,000. CBIZ Investment Advisory Services LLC grew its stake in shares of Chemed by 64.7% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 56 shares of the company's stock worth $30,000 after acquiring an additional 22 shares in the last quarter. Tortoise Investment Management LLC grew its stake in shares of Chemed by 77.3% in the 4th quarter. Tortoise Investment Management LLC now owns 78 shares of the company's stock worth $41,000 after acquiring an additional 34 shares in the last quarter. Brown Brothers Harriman & Co. grew its position in Chemed by 633.3% during the fourth quarter. Brown Brothers Harriman & Co. now owns 88 shares of the company's stock valued at $47,000 after buying an additional 76 shares during the period. Finally, SRS Capital Advisors Inc. grew its position in Chemed by 39.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 135 shares of the company's stock valued at $72,000 after buying an additional 38 shares during the period. 95.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on CHE. Wall Street Zen raised shares of Chemed from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Royal Bank of Canada boosted their target price on shares of Chemed from $667.00 to $674.00 and gave the company an "outperform" rating in a report on Monday, April 28th.

Chemed Price Performance

Shares of NYSE:CHE traded up $1.43 during mid-day trading on Friday, reaching $574.62. 79,372 shares of the company traded hands, compared to its average volume of 103,140. The company's 50 day moving average price is $580.66 and its 200-day moving average price is $565.90. The firm has a market cap of $8.41 billion, a PE ratio of 29.04, a PEG ratio of 2.15 and a beta of 0.59. Chemed Co. has a 52 week low of $512.12 and a 52 week high of $623.61.

Chemed (NYSE:CHE - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The company reported $5.63 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.04. Chemed had a return on equity of 27.86% and a net margin of 12.69%. The firm had revenue of $646.94 million during the quarter, compared to the consensus estimate of $641.78 million. During the same period in the prior year, the company earned $5.20 EPS. The company's quarterly revenue was up 9.8% compared to the same quarter last year. On average, research analysts predict that Chemed Co. will post 21.43 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 17th. Stockholders of record on Thursday, May 29th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Thursday, May 29th. This represents a $2.00 annualized dividend and a dividend yield of 0.35%. Chemed's dividend payout ratio is currently 9.74%.

Insider Buying and Selling at Chemed

In other Chemed news, EVP Spencer S. Lee sold 1,500 shares of the firm's stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $577.86, for a total value of $866,790.00. Following the completion of the sale, the executive vice president now directly owns 16,127 shares of the company's stock, valued at $9,319,148.22. This trade represents a 8.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin J. Mcnamara sold 1,000 shares of the firm's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $615.33, for a total value of $615,330.00. Following the completion of the sale, the chief executive officer now directly owns 101,679 shares of the company's stock, valued at $62,566,139.07. This trade represents a 0.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 7,500 shares of company stock worth $4,401,120 over the last quarter. Insiders own 3.29% of the company's stock.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.